Cholesteatoma, Congenital

先天性胆脂瘤

更新于：2025-01-23

基本信息

别名

CHOLESTEATOMA, CONGENITAL、Cholesteatoma, Congenital、Congenital cholesteatoma

+ [4]

简介-

关联

项与先天性胆脂瘤相关的临床试验

JPRN-jRCTb032190216

/ CompletedN/AIIT

Hard tissue reconstruction in surgery for middle ear cholesteatoma using implant-type tissue-engineered cartilage - Middle ear hard tissue reconstruction using regenerative medicine

开始日期2017-09-07

申办/合作机构-

100 项与先天性胆脂瘤相关的临床结果

登录后查看更多信息

100 项与先天性胆脂瘤相关的转化医学

登录后查看更多信息

0 项与先天性胆脂瘤相关的专利（医药）

登录后查看更多信息

456

项与先天性胆脂瘤相关的文献（医药）

2025-02-01·Otolaryngologic Clinics of North America

Outcomes with Management of Cholesteatoma

Review

作者: Lee, Kenneth ; Perkins, Elizabeth L. ; Tan, Donald ; Perkins, Elizabeth L ; Schauwecker, Natalie

This article provides an expert summary of the immense amount of outcomes research in cholesteatoma surgery. Specific topics discussed include canal wall-up versus canal wall-down surgery, ossicular chain reconstruction, endoscopic ear surgery, disease-specific quality-of-life outcomes, and congenital cholesteatoma.

2025-02-01·The Laryngoscope

EAONO/JOS, STAMCO, ChOLE & Potsic Staging of 271 Pediatric Cholesteatoma: Evidence‐Based Mod‐Pot Staging System

Article

作者: Couloigner, Vincent ; Chatelet, Florian ; Denoyelle, Françoise ; Marchand, Gauthier ; Atallah, Sarah ; Leboulanger, Nicolas ; Célérier, Charlotte ; Garabédian, Erea‐Noël ; Loundon, Natalie ; Simon, François

ObjectiveThe objective was to assess Potsic, EAONO/JOS, STAMCO, and ChOLE cholesteatoma staging systems in a large homogenous pediatric cohort with long‐term follow‐up and propose an evidence‐based improved version.Study designCohort study.SettingRetrospective study in a tertiary referral center.MethodsChildren with congenital or acquired cholesteatoma who underwent surgery between 2008 and 2015 and had a minimum of five years follow‐up were included. ROC areas under curve (AUCs) were performed for the residual disease proportion, total number of surgeries, hearing, and C‐index for recurrence proportion at the last follow‐up.ResultsData from 271 ears with cholesteatoma were collected. Mean age at diagnosis was 7.9 years and 77 (28%) were congenital. Almost all patients (99%) had a canal wall up approach. The mean follow‐up was 97.8 months. The Potsic classification, initially designed for congenital cholesteatoma, had the highest AUCs for residual disease rate and for number of surgeries outcomes (respectively 0.73 [0.67–0.78] and 0.71 [0.66–0.77]). For recurrence rate, all the classifications' C‐index were low (<0.7). For postoperative hearing, STAMCO ossicular subscore had the highest AUC (0.73 [0.67–0.79]). The Mod‐Pot staging system (modified Potsic), including stapes superstructure status and anterior epitympanum or supratubal involvement, improved the Potsic performance especially for postoperative hearing with AUC 0.73 [0.67–0.80], p < 0.001.ConclusionThe Potsic, ChOLE, EAONO/JOS, and STAMCO cholesteatoma classifications may be used in children, but in this specific population, their contribution remains limited to predict outcome. The Mod‐Pot classification improved the performance of pediatric cholesteatoma classification while remaining simple and intuitive.Level of Evidence3 Laryngoscope, 135:908–919, 2025

2025-02-01·Otolaryngologic Clinics of North America

Congenital Cholesteatoma

Review

作者: Alford, Bobby R. ; Alfonso, Kristan P ; Alfonso, Kristan P.

Congenital cholesteatoma is a cyst of keratinizing squamous cell epithelium in the setting of an intact tympanic membrane, in a patient without a history of otorrhea, tympanic membrane perforation, or otologic surgery. The most common presentation of a congenital cholesteatoma is that of an asymptomatic pearly white mass in the anterosuperior quadrant of the tympanic cavity. The etiology of congenital cholesteatoma has been debated at length, with the leading theory being the epithelial rest theory. Treatment for congenital cholesteatoma is surgical, with advances in endoscopic ear surgery allowing for improved intraoperative visualization and postoperative lowered recidivism rates.

分析

对领域进行一次全面的分析。

或

查看完整样例数据

Eureka LS:

全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步

立即开始免费试用!

智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。

立即开始数据试用!

智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。